1 1 dial infarction (MI) is causal to progressive cardiac which may target receptors on multiple cardiac cell types dysfunction. Initially, the myocardium responds to the loss [6, 7] . Incidence of heart failure is marked by the reof sarcomeric contractile units with the induction of programming of gene expression in affected cardiac cells compensatory cardiac growth. In clinical terms, this rei.e. the hypertrophic (or fetal) gene program in cardiac sponse is marked by normalization of wall stress and myocytes and modulation of fibroblast phenotype (i.e. the preservation of pump function within normal limits. The appearance of cardiac myofibroblasts) and metabolism severity of eventual secondary cardiac hypertrophy is [6, 8, 9 ]. The latter alterations may persist even in the variable depending on the initial size of infarction [1, 2] . In absence of continued chronic biomechanical stress, for the event of a large MI, the affected ventricular chamber example when afterload reduction therapy is initiated [5] . may undergo dilatation at a point well after the initial
The cumulative effects of these changes are cardiac insult [3] . At this stage of hypertrophy, increased myocyte myocyte dysfunction and overt cardiac fibrosis in areas size is associated with decreased intrinsic cardiac peradjacent to and remote from the site of infarction, and formance [4] . In other words, the heart reaches a decurrent pharmacological strategies directed at their reversal compensated hypertrophic state. Furthermore, it is clear have proven to be partially effective when considering the that the pathogenic progression to heart failure in post-MI broad spectrum of subcellular abnormalities that mark patients involves both cardiac myocytes and nonmyocytes pathological hypertrophy and failure [5, 6] . Recent evi-(i.e. myofibroblasts), and that these cell groups respond dence points to the possible contributory role of myocyte independently to volume overload [5] . Despite the current apoptosis manifested as either sporadic or massive acute extensive armamentum of pharmacological interventions myocyte cell drop-out in chronic cardiac disease and available to the clinician to combat this syndrome, the infarction, respectively, in the development of heart failure prognosis for patients who manage to survive the acute [10] . For example, during chronic aortic pressure overload, phase of a large MI remains grim. An improved underthe occurrence of sporadic cardiac myocyte apoptosis has standing of endogenous adaptive changes of the myocarbeen suggested to effect the transition between compendium may provide a basis for exploitation in delaying the sated and decompensated cardiac hypertrophy [11] . In onset of maladaptive hypertrophy.
contrast, there is little subtlety in the nature of the acute ultrastructural havoc typical of myocyte necrosis in acute MI, and the arguments for the putative benefits of cardiac 1. Mechanisms of heart failure after myocardial myocyte preservation in this setting require little emphasis. infarction
The development of (i) abortive therapeutic strategies either to minimize the extent of infarction via rapid The complexity of post-MI heart failure is marked by reperfusion or (ii) management therapies to maintain the multitude of triggers that contribute to its pathogenesis.
adequate post-MI cardiac function in patients with healed infarcts are characterized by a modicum of success and continue to evolve. Investigation of endogenous cardio-satory response at or near the time of infarction is an directly activates ERK1 / 2. This pattern of activation exciting and novel avenue for therapy, partially because of seems to be unique to HGF insofar as Akt is not also a the lack of complete efficacy of current interventions in primary target for phosphorylation in the presence of HGF. halting the progression and severity of the disease. The
The current data also show that the c-Met receptor is concept of infarct size reduction vis a vis reduction of localized to cardiac myocytes and vascular endothelial myocyte loss through necrosis and / or apoptosis at the time cells both on myocardial infarct border zone and in heart of infarction bears investigation. While the suppression of remote to the infarct. The current finding provides support proinflammatory cytokines is an emerging concept for the for the supposition that myocytes are a primary target of treatment of heart failure [12] [13] [14] , the use of cardioendogenous HGF. Nevertheless, other recent work has protective cytokines to modulate the progression of acute focused on the anti-fibrotic role of HGF and the inischemic cardiac damage [15] [16] [17] and for alleviation of volvement of cardiac fibroblasts [31] . Whether the effects heart failure represents a novel mode of therapy [18, 19] . [20] . Their general hypothesis was that increased putative adaptive) mechanism in myocardial infarction. expression and activation of HGF itself as well as c-Met /
The strong positive correlation of HGF's antioxidant HGF receptors in cardiac myocytes might confer cardiopeffects and its upregulation in tissues bordering the infarcrotection to cardiac myocytes at risk. The in vitro system ted heart and remote to the infarct site are exciting (rat -chronic infarction) and in vivo models (to assess the developments with considerable promise for development. effects of HGF in acute oxidant stress) used in these studies are suitable for the examination of cardiac myocyte function as well as the functional and morphological References characteristics of post-MI hearts. In particular, the rat post-MI model of heart failure is useful for the examina- The data presented is provocative and provides a signifi- 
activates ERK1 / 2
[4] Colucci WS, Braunwald E. Pathophysiology of heart failure. In: Braunwald E, editor, Heart disease, Philadelphia. PA: W.B. Saunders, 1997, pp. 394-420.
It is well entrenched in the literature that the function of noninfarcted control hearts, and that HGF itself is able to ing myocardial ischemia and reperfusion [28] and has been Gia2 and Gsa in myofibroblasts localized to the infarct scar in heart identified as a marker of acute MI in humans [29] . HGF failure due to myocardial infarction. Cardiovasc Res 1998;41:575-has also attracted attention for its angiogenic properties 585. [30] . Evidence for this mode of protection have been 
